Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
NCT03654768Phase 2Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Oct 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in chronic myeloid leukemia (CML) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Rate of Molecular Response 4.5 at 12 months. Started Oct 2018; status: active, not recruiting.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03654768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654768.